Composition for diagnosing parkinson's disease containing adipose tissue-derived mesenchymal stromal cell

Abstract

The present invention relates to a composition for diagnosing a Parkinson's disease comprising mesenchymal stromal cells derived from adipose tissue, a method of providing information for diagnosing Parkinson's disease and/or the extent of the disease progression, a biomarker for diagnosing a Parkinson's disease, and a method of screening a drug candidate treating Parkinson's disease where the drug candidate is a target of the biomarker.

1 . A composition for diagnosing a disease, comprising a mesenchymal stromal cell derived from adipose tissue, wherein the disease is selected from the group consisting of Parkinson's disease, Alzheimer's disease, Huntington's disease, hereditary dystonia, hereditary dyskinesia, and metabolic disease. 
     
     
         2 . The composition according to  claim 1 , wherein the composition is used for diagnosing the Parkinson's disease. 
     
     
         3 . A method of providing information for diagnosing a disease, comprising the steps of separating a mesenchymal stromal cell derived from adipose tissue of a subject; assaying a gene expression pattern of the mesenchymal stromal cell; and determining the presence of a disease by analyzing the assayed result,
 wherein the disease is selected from the group consisting of Parkinson's disease, Alzheimer's disease, Huntington's disease, hereditary dystonia, hereditary dyskinesia, and metabolic disease.   
     
     
         4 . The method of providing information for diagnosing a disease according to  claim 3 , wherein the disease is Parkinson's disease. 
     
     
         5 . The method of providing information for diagnosing a disease according to  claim 4 , wherein the disease of a subject is diagnosed to be Parkinson's disease, in case there is an increased expression of at least one gene in the mesenchymal stromal cells derived from the adipose tissue selected from the group consisting of ITGA8(Genbank accession No: NM — 003638), CTSH(Genbank accession No: NM — 004390), CCRL1(Genbank accession No: NM — 178445), TGFB3(Genbank accession No: NM — 003239), DRD1(Genbank accession No: NM — 000794), GNA14(Genbank accession No: NM — 004297), PENK(Genbank accession No: NM — 006211), PRG4(Genbank accession No: NM — 005807), LGR5(Genbank accession No: NM — 003667), HLA-DPA1(Genbank accession No: NM — 033554), SCUBE3(Genbank accession No: NM — 152753), HSPA2(Genbank accession No: NM — 021979), RELN(Genbank accession No: NM — 005045), EDNRB(Genbank accession No: NM — 000115), ITGA2(Genbank accession No: NM — 002203), SLC6A6(Genbank accession No: NM — 003043), F2RL2(Genbank accession No: NM — 004101), CDK6(Genbank accession No: NM — 001259), AKR1B1(Genbank accession No: NM — 001628), MMP8(Genbank accession No: NM — 002424), ID1(Genbank accession No: NM — 181353), NEFM(Genbank accession No: NM — 005382), ATP1B1(Genbank accession No: NM — 001677), TNFRSF11B(Genbank accession No: NM — 002546), and TNFRSF10D(Genbank accession No: NM — 003840), or a decreased expression of at least gene selected from the group consisting of BEX1(Genbank accession No: NM — 018476), IL8(Genbank accession No: NM — 000584), and CXCL6(Genbank accession No: NM — 002993). 
     
     
         6 . A method of screening a drug treating Parkinson's disease, comprising the steps of:
 contacting a candidate compound with a mesenchymal stromal cell derived from adipose tissue; and   assaying a gene expression pattern in the mesenchymal stromal cell,   wherein the candidate compound is determined as a drug treating Parkinson's disease, in case difference of gene expression pattern is observed in the mesenchymal stromal cells between the treatment and non-treatment of the drug candidate, and the gene expression pattern is obtained from one or more selected from the group consisting of ITGA8(Genbank accession No: NM — 003638), CTSH(Genbank accession No: NM — 004390), CCRL1(Genbank accession No: NM — 178445), TGFB3(Genbank accession No: NM — 003239), DRD1(Genbank accession No: NM — 000794), GNA14(Genbank accession No: NM — 004297), PENK(Genbank accession No: NM — 006211), PRG4(Genbank accession No: NM — 005807), LGR5(Genbank accession No: NM — 003667), HLA-DPA1(Genbank accession No: NM — 033554), SCUBE3(Genbank accession No: NM — 152753), HSPA2(Genbank accession No: NM — 021979), RELN(Genbank accession No: NM — 005045), EDNRB(Genbank accession No: NM — 000115), ITGA2(Genbank accession No: NM — 002203), SLC6A6(Genbank accession No: NM — 003043), F2RL2(Genbank accession No: NM — 004101), CDK6(Genbank accession No: NM — 001259), AKR1B1(Genbank accession No: NM — 001628), MMP8(Genbank accession No: NM — 002424), ID1(Genbank accession No: NM — 181353), NEFM(Genbank accession No: NM — 005382), ATP1B1(Genbank accession No: NM — 001677), TNFRSF11B(Genbank accession No: NM — 002546), TNFRSF10D(Genbank accession No: NM — 003840), BEX1(Genbank accession No: NM — 018476), IL8(Genbank accession No: NM — 000584), and CXCL6(Genbank accession No: NM — 002993).   
     
     
         7 . The method of screening a drug treating Parkinson's disease according to  claim 6 , wherein the drug candidate is determined as a drug treating Parkinson's disease, in case the treatment of drug candidate results in an increased expression of at least one gene selected from the group consisting of ITGA8(Genbank accession No: NM — 003638), CTSH(Genbank accession No: NM — 004390), CCRL1(Genbank accession No: NM — 178445), TGFB3(Genbank accession No: NM — 003239), DRD1(Genbank accession No: NM — 000794), GNA14(Genbank accession No: NM — 004297), PENK(Genbank accession No: NM — 006211), PRG4(Genbank accession No: NM — 005807), LGR5(Genbank accession No: NM — 003667), HLA-DPA1(Genbank accession No: NM — 033554), SCUBE3(Genbank accession No: NM — 152753), HSPA2(Genbank accession No: NM — 021979), RELN(Genbank accession No: NM — 005045), EDNRB(Genbank accession No: NM — 000115), ITGA2(Genbank accession No: NM — 002203), SLC6A6(Genbank accession No: NM — 003043), F2RL2(Genbank accession No: NM — 004101), CDK6(Genbank accession No: NM — 001259), AKR1B1(Genbank accession No: NM — 001628), MMP8(Genbank accession No: NM — 002424), ID1(Genbank accession No: NM — 181353), NEFM(Genbank accession No: NM — 005382), ATP1B1(Genbank accession No: NM — 001677), TNFRSF11B(Genbank accession No: NM — 002546), and TNFRSF10D(Genbank accession No: NM — 003840), or a decreased expression of at least one gene selected from the group consisting of BEX1(Genbank accession No: NM — 018476), IL8(Genbank accession No: NM — 000584), and CXCL6(Genbank accession No: NM — 002993), relative to non-treatment of the drug candidate.